Enhanc3d Genomics

Enhanc3D Genomics appoints Dr Daniel Turner as chief scientific officer

Appointment forms part of ongoing plans for continued development of the GenLink3D genomics platform and formation of strategic commercial and academic partnerships 31 January 2024 – Cambridge, UK – Enhanc3D Genomics, a company developing disruptive technologies to unlock the 3D spatial genome for target and biomarker discovery, today announced the appointment of Dr Daniel Turner...

ENHANC3D GENOMICS Awarded QuickFire Challenge Grant

Cambridge, UK - 26 May 2022: ENHANC3D GENOMICS ('Enhanc3D'), a biotechnology company unlocking the full potential of the human 3D genome to accelerate patient-centric medicine, announces it has been selected as one of the awardees under Johnson & Johnson Innovationís Immunology Innovations QuickFire Challenge. The Challenge called for innovative companies with transformative potential solutions aiming...
Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, Cambridge CB2 0AW